Detalhe da pesquisa
1.
Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial.
Eur Heart J
; 45(13): 1159-1169, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38291599
2.
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.
Circulation
; 143(5): 470-478, 2021 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33185476
3.
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.
Eur Heart J
; 42(47): 4821-4829, 2021 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34537830
4.
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
Circulation
; 141(8): 616-623, 2020 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31707849
5.
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Circulation
; 141(20): 1600-1607, 2020 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32223429
6.
Long-Term Incidence of Stroke and Dementia in ASCOT.
Stroke
; 52(10): 3088-3096, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192893
7.
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
Lancet
; 396(10263): 1637-1643, 2020 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186535
8.
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjectsã- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.
Circ J
; 85(11): 2063-2070, 2021 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33980763
9.
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Circulation
; 139(12): 1483-1492, 2019 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30586750
10.
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Stroke
; 51(5): 1546-1554, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32312223
11.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
N Engl J Med
; 376(18): 1713-1722, 2017 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28304224
12.
Cognitive Function in a Randomized Trial of Evolocumab.
N Engl J Med
; 377(7): 633-643, 2017 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-28813214
13.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Circulation
; 137(4): 338-350, 2018 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133605
14.
Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Circulation
; 138(8): 756-766, 2018 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29626068
15.
Inflammatory and Cholesterol Risk in the FOURIER Trial.
Circulation
; 138(2): 131-140, 2018 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29530884
16.
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Lancet
; 392(10153): 1127-1137, 2018 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30158072
17.
Analysis with the exome array identifies multiple new independent variants in lipid loci.
Hum Mol Genet
; 25(18): 4094-4106, 2016 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27466198
18.
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Lancet
; 389(10088): 2473-2481, 2017 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28476288
19.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.
Lancet
; 390(10106): 1962-1971, 2017 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28859947
20.
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects.
N Engl J Med
; 383(22): 2182-2184, 2020 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33196154